Gout Death: What Is the Link to Mortality?

Gout raises the risk of dying earlier than expected, with large studies consistently finding that people with gout face roughly a 15 to 25 percent higher rate of death from all causes compared to people without the disease. The excess risk is driven mostly by cardiovascular disease and kidney failure, though the picture gets more complicated once you account for the metabolic conditions that tend to travel alongside gout. Whether gout itself is pulling the trigger or simply standing next to the smoking gun has been one of the more stubborn questions in rheumatology.

How Large Is the Mortality Gap?

Several large cohort studies have tried to pin down exactly how much gout shortens life. A long-running study of over 50,000 men in the Health Professionals Follow-Up Study found that men with gout had about a 28 percent higher risk of dying from any cause and a 38 percent higher risk of dying from cardiovascular disease, even after adjusting for other known risk factors.¹ A Swedish cohort study reported a similar pattern: gout was associated with a 24 percent increase in all-cause mortality after adjusting for age and sex.² And a UK-based study of over 68,000 gout patients found a 17 percent increase in all-cause mortality overall.³

Here is where it gets interesting. When researchers adjust more aggressively for the conditions that cluster with gout, like obesity, high blood pressure, diabetes, and kidney disease, the mortality gap shrinks substantially. A large U.S. Veterans Health Administration study found that the excess risk essentially disappeared once those comorbidities were taken into account.⁴ The Swedish cohort saw the same thing: after full adjustment, the overall mortality increase dropped to about 3 percent and was no longer statistically significant.²

This creates an honest interpretive problem. One reading is that gout itself is harmless and the real killers are the metabolic neighbors. Another is that gout contributes to a cascade of vascular damage that is difficult to fully separate from those neighbors because they share the same underlying biology. The truth probably sits somewhere between the two, and the answer may differ depending on whether you are talking about chronic high uric acid or acute gout flares.

Gout Flares and the Cardiovascular Spike

One of the more striking findings in recent gout research is that a single gout flare can temporarily raise the risk of a heart attack or stroke. A 2022 study published in JAMA used a case-crossover design and found that the odds of a cardiovascular event were roughly doubled in the 60 days following a gout flare, compared to periods further from any flare. The elevated risk persisted, though at lower levels, for about 120 days before fading.⁵ A commentary in Nature Reviews Rheumatology noted that these findings reframe gout flares from an “inconsequential episode of acute joint pain” to a potential cardiovascular danger signal, and that how flares are treated may influence the risk.⁶

The implication is practical: every gout flare that goes undertreated or uncontrolled is not just a few days of miserable joint pain. It is a window of heightened vascular vulnerability. This gives urgency to flare prevention and to aggressive management when flares do occur, especially for patients who already have cardiovascular disease or its risk factors.

How Uric Acid Damages Blood Vessels

The biological story connecting gout to cardiovascular death centers on uric acid and inflammation. Elevated uric acid promotes the generation of reactive oxygen species, which damage the inner lining of blood vessels and contribute to arterial stiffness.⁷ This endothelial dysfunction appears to involve the activation of xanthine oxidase, an enzyme in the uric acid production pathway, as well as the direct uptake of uric acid into endothelial cells through specific transporters.⁸

At the same time, there is growing evidence of a more direct inflammatory link within blood vessel walls. A study examining atherosclerotic plaques from patients with peripheral artery disease found that higher uric acid levels were associated with greater expression of NLRP3 inflammasome components and gasdermin-D, both markers of a specific inflammatory cell-death pathway, in the plaque tissue itself.⁹ Interestingly, the researchers did not find urate crystals deposited directly on artery walls, suggesting that the vascular harm comes more from the systemic inflammatory environment that high uric acid creates rather than from crystals physically lodging in arteries the way they do in joints.

The Kidney Disease Pathway

Kidney disease is the other major route by which gout contributes to early death, and the numbers are stark. A meta-analysis of observational studies found that about one in four gout patients had at least moderate chronic kidney disease, and after adjusting for other risk factors, gout more than doubled the odds of having it.¹⁰

The relationship between gout and the kidneys is bidirectional. Uric acid is excreted primarily through the kidneys, so as kidney function declines, uric acid levels rise, promoting more gout. Meanwhile, chronic uric acid exposure may itself contribute to kidney damage through crystal deposition and inflammation in the renal tubules. This feedback loop makes it genuinely difficult to know which came first in any given patient. A prospective study from Singapore tried to address this by looking at mortality only among patients with at least five years of follow-up after their gout diagnosis. Even with that conservative approach, gout was associated with nearly a fivefold increase in kidney disease mortality.¹¹ The same study found a 38 percent increase in coronary heart disease death, putting both organ systems squarely in the crosshairs.

The Metabolic Syndrome Overlap

One reason gout patients die earlier is that gout rarely arrives alone. Obesity, high blood pressure, insulin resistance, and abnormal blood lipids cluster together under the umbrella of metabolic syndrome, and gout tends to sit right in the middle of that cluster. A population-based study found that moderate to high metabolic syndrome severity was common among gout patients, and each unit increase in a metabolic syndrome severity score was significantly associated with higher risk of death from all causes, heart disease, diabetes, and hypertension.¹²

This is part of why the gout-specific mortality signal weakens so much after full adjustment in the epidemiological studies mentioned earlier. You can’t easily peel apart gout from the metabolic conditions it shares biological roots with. But that does not mean gout is irrelevant to the death risk. Metabolic syndrome and hyperuricemia feed each other: insulin resistance reduces the kidney’s ability to clear uric acid, and high uric acid promotes the endothelial dysfunction and inflammation that accelerate metabolic disease. Treating them as separate, independent problems misses the way they amplify each other.

Why Women With Gout Face a Larger Relative Risk

Women develop gout far less often than men, but when they do, the mortality signal is proportionally larger. The UK study found that gout increased the hazard of all-cause death by 23 percent in women compared to 15 percent in men.³ The Swedish cohort found a similar pattern: in fully adjusted models, gout was associated with a 10 percent increase in all-cause mortality in women but no significant increase in men.²

The likely explanation is partly statistical: because women have a lower background rate of cardiovascular disease and death, gout adds a relatively larger increment. But there may be biological factors as well. Women who develop gout tend to be older and postmenopausal, since estrogen helps the kidneys excrete uric acid. By the time gout surfaces, these women often already have significant cardiovascular and renal burden. There is also evidence from a U.S. study that the premature mortality gap related to gout is prominent among Black individuals and that this gap has not been closing over time.¹³

Does Lowering Uric Acid Save Lives?

If high uric acid drives the excess death risk, you would expect that bringing it down with medication should improve survival. The evidence here is encouraging but not yet definitive. A population-based study found that starting allopurinol, the most commonly prescribed uric acid-lowering drug, was associated with about an 11 percent lower risk of all-cause mortality in the general population and about a 19 percent lower risk among patients specifically with gout.¹⁴ However, a systematic review and meta-analysis pooling data from studies of gout patients found that the association between allopurinol use and reduced all-cause mortality did not quite reach statistical significance.¹⁵

What does seem clearer is that allopurinol may reduce heart attacks specifically. A separate systematic review and meta-analysis found a significantly reduced risk of myocardial infarction with allopurinol, though there was no significant effect on stroke or cardiovascular mortality.¹⁶ Whether these benefits reflect the direct effects of lower uric acid or the reduction in xanthine oxidase activity (and thus less oxidative stress) remains debated.

There is also strong evidence that actually achieving a low uric acid target matters. One study of gout patients on urate-lowering therapy found that those who failed to get their serum uric acid below 6 mg/dL had more than double the risk of dying from any cause and roughly double the risk of cardiovascular death, compared to those who hit the target.¹⁷ Getting to target requires both the right dose and actually taking the medication consistently, yet adherence to gout therapy is notoriously poor. A five-year follow-up study found that patients with the lowest medication adherence were far more likely to have flares and far less likely to reach their uric acid target, compared to those who stuck with treatment.¹⁸

The Febuxostat Controversy

The question of which uric acid-lowering drug to use became unexpectedly fraught in 2018, when the CARES trial reported that febuxostat, an alternative to allopurinol, was associated with higher all-cause and cardiovascular mortality. All-cause mortality was about 22 percent higher and cardiovascular mortality about 34 percent higher in the febuxostat group.¹⁹ The FDA subsequently added a boxed warning to febuxostat, and many clinicians pulled back from prescribing it.

But the CARES trial had major problems, including a very high dropout rate of about 57 percent, and most of the excess deaths occurred in patients who had already stopped taking the study drug. When a European trial called FAST addressed the same question with better retention, febuxostat turned out to be not inferior to allopurinol on cardiovascular outcomes.²⁰ A large U.S. population-based cohort study of older gout patients initiating one drug or the other also found essentially identical cardiovascular risk between the two.²¹ The emerging consensus is that febuxostat is probably not more dangerous than allopurinol, though the CARES boxed warning remains in place in the United States as of this writing.

Colchicine and Its Dual Role

Colchicine has been used for gout flares for centuries, but it has recently gained a second life as a cardiovascular drug. Research in the early 21st century showed that low-dose colchicine can add to secondary prevention of major adverse cardiovascular events, likely by dampening the inflammatory pathways that destabilize arterial plaques.²² In gout patients specifically, one study found that colchicine users without chronic kidney disease had a substantially lower rate of developing coronary artery disease during follow-up.²³

This creates an interesting situation where a drug that gout patients already take for flare management may simultaneously be protecting their hearts. The cardiovascular trials of colchicine were run mainly in non-gout populations with established coronary disease, so the degree to which benefits translate directly to gout patients is still being worked out. But the pharmacological logic is appealing: if acute gout inflammation can trigger cardiovascular events, and colchicine suppresses that inflammation, the drug may be pulling double duty.

Racial Disparities in Gout Outcomes

Gout does not affect all populations equally, and neither does its mortality burden. Black Americans have a higher prevalence of gout than white Americans and are less likely to receive guideline-based gout care.²⁴ A recent study using U.S. national survey data found that the premature mortality gap associated with gout has not been closing over time and is particularly prominent among Black individuals, even after accounting for differences in serum uric acid levels and standard cardiovascular risk factors.¹³

The reasons are layered. Lower rates of insurance, fewer rheumatology referrals, undertreated comorbidities, and systemic barriers to consistent medication access all contribute. Gout is sometimes dismissed by clinicians as a self-inflicted condition related to diet, which can lead to less aggressive treatment, especially for patients who are already marginalized in the healthcare system. The mortality data suggest that this dismissive attitude has real consequences.

When Gout Treatment Itself Is Dangerous

Rarely, the medications used to treat gout can themselves cause serious harm. Allopurinol is the most commonly prescribed uric acid-lowering drug worldwide, and in a small fraction of patients it triggers severe cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. These are life-threatening skin conditions involving widespread skin detachment. A study from southern Italy reported 26 cases of toxic epidermal necrolysis associated with allopurinol, and half of those patients died.²⁵ A larger study comparing drug-induced severe skin reactions found that allopurinol-induced cases had a mortality rate of about 18 percent, more than double the rate for other drug-induced cases.²⁶

These reactions are strongly associated with a genetic variant called HLA-B*5801, which is more common in people of Southeast Asian, Korean, and African American descent. Guidelines now recommend testing for this variant before starting allopurinol in high-risk populations. For the vast majority of patients, allopurinol is safe and effective, but the existence of this rare, potentially fatal side effect underscores why gout treatment decisions deserve more care than they often receive.

Why Humans Are Stuck With Uric Acid

Most mammals have an enzyme called uricase that breaks down uric acid into a more soluble compound that is easily excreted. Humans, along with other great apes, lost functional uricase millions of years ago through a series of genetic mutations. One widely cited hypothesis proposed that this happened because uric acid acts as an antioxidant and could compensate for the earlier loss of the ability to synthesize vitamin C, which occurred roughly 65 million years ago. But a detailed study resurrecting ancient uricase proteins found that the key loss of uricase activity occurred between 20 and 30 million years ago, long after the loss of vitamin C synthesis, making the two events appear unrelated.²⁷

Whatever the evolutionary reason, the result is that human blood uric acid levels are far higher than those of most other mammals, leaving us uniquely vulnerable to gout and its downstream consequences. Other proposed advantages of high uric acid include its role in maintaining blood pressure in low-salt environments and its possible neuroprotective effects, but none of these hypotheses has been firmly established. What is established is that the trait creates a permanent biological tension: a molecule that can act as an antioxidant at normal concentrations becomes a source of inflammation, crystal deposition, and vascular damage when levels climb too high.

1
PubMed. Independent impact of gout on mortality and risk for coronary heart disease
2
Frontiers in Medicine. Incident Gout: Risk of Death and Cause-Specific Mortality in Western Sweden: A Prospective, Controlled Inception Cohort Study
3
PubMed Central. Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Non-Cardiovascular Related Deaths
4
PubMed Central. Cause-Specific Mortality in Patients with Gout in the United States Veteran’s Health Administration: A Matched Cohort Study
5
JAMA. Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout
6
Nature Reviews Rheumatology. Beyond joint pain, could each gout flare lead to heart attack?
7
PubMed Central. Uric Acid and Arterial Stiffness
8
Hypertension Research. Is uric acid a causal risk factor of arterial stiffness in patients with hypertension?
9
PubMed. Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia
10
PubMed Central. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies
11
PubMed Central. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study
12
PubMed. The relationship between metabolic syndrome severity and the risk of mortality in gout patients: a population-based study
13
PubMed Central. Unclosing Premature Mortality Gap Among Patients With Gout in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors
14
PubMed Central. Allopurinol initiation and all-cause mortality in the general population
15
PubMed. Mortality in Patients With Gout Treated With Allopurinol: A Systematic Review and Meta-Analysis
16
PLOS ONE. Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis
17
PubMed Central. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality
18
Rheumatology. Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study
19
PubMed. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
20
The Lancet. Cardiovascular safety of febuxostat or allopurinol in patients with gout
21
PubMed Central. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study
22
PubMed Central. Colchicine’s Role in Cardiovascular Disease Management
23
PubMed Central. Colchicine Use and Incident Coronary Artery Disease in Male Patients With Gout
24
PubMed Central. Racial and gender disparities among patients with gout
25
PubMed Central. Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy
26
PubMed. Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions
27
PubMed Central. Phylogenetic Articulation of Uric Acid Evolution in Mammals and How It Informs a Therapeutic Uricase